Raphael Pharmaceutical Inc. (RAPH): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Raphael Pharmaceutical Inc. (RAPH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001415397 0001415397 2026-07-16 2026-07-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report
How this was made
The 30-second read
Why it matters
The newest concrete information is the resignation of the CFO and General Counsel and the appointment of a new CFO effective July 16, 2026, which can affect investor confidence in financial reporting oversight and near-term execution.
Market read
Executive turnover at the CFO/GC level is a governance signal and can drive short-term sentiment and volatility, even without new financial metrics.
What to watch
Traders may overreact to turnover without additional context; the filing lacks reasons, transition terms, or any new financial targets, so follow-up filings (employment agreements, compensation, future guidance) matter more.
Background
This is an SEC Form 8-K (Item 5.02) reporting director/officer departures and a compensatory-officer appointment, dated July 16, 2026.
Ticker impact
Raphael Pharmaceutical disclosed CFO and General Counsel resignations and appointed Uri Tadelis as CFO effective July 16, 2026.
Likely modest, sentiment-driven volatility around governance/execution expectations rather than a fundamental repricing from this filing alone.
The 8-K is a primary disclosure of executive changes (CFO, GC, director) and a new CFO appointment, without any accompanying earnings, guidance, financing, or legal/clinical catalyst.
Market effects
No direct sector read-across is provided; impact is company-specific governance and finance-function continuity.
Limited, as the filing is US SEC disclosure for a company headquartered in Israel.
Low, unless the new CFO signals a broader strategic or financing plan, which is not disclosed here.
Counterpoint
The resignations are described as not due to disagreements, and the company promptly appointed a new CFO, which can reduce uncertainty versus a prolonged vacancy.
Key entities
- issuerRaphael Pharmaceutical Inc.
Subject of the 8-K, reporting executive departures and a new CFO appointment.
- officerAjay Kumar Dhadha
Resigned as Chairman of the Board and Director effective June 30, 2026.
- officerGuy Ofir
Resigned as CFO, General Counsel, and Director effective July 16, 2026.
- officerUri Tadelis
Appointed Chief Financial Officer effective July 16, 2026.
